Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BI 836845 + enzalutamide
- Development stage
- Unknown
- Lead developer
- Boehringer Ingelheim
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
**BI 836845 + enzalutamide** is a combination therapy under clinical investigation for the treatment of metastatic castration-resistant prostate cancer (mCRPC), especially in patients previously treated with and failed docetaxel and abiraterone. BI 836845 (also known as xentuzumab) is a monoclonal antibody that neutralizes insulin-like growth factors IGF-1 and IGF-2, thereby inhibiting downstream signaling pathways involved in tumor growth and survival. Enzalutamide is an androgen receptor antagonist that blocks androgen receptor signaling, a key driver in prostate cancer progression. The rationale for the combination lies in overcoming resistance to enzalutamide by inhibiting compensatory growth signaling through the IGF pathway[1][5].
- Other names
- xentuzumab + enzalutamide
02
Targets
IGF-1 (Insulin-like growth factor 1)IGF2 (Insulin-like growth factor 2)AR (Adrenergic receptors)
Beyond the preview
Go deeper on BI 836845 + enzalutamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BI 836845 + enzalutamide.